Consultez les derniers articles autour de la maladie de Willebrand
Dernière mise à jour : Vendredi 23 octobre 2026The efficacy and safety of prophylaxis with wilate, a plasma-derived von Willebrand factor/factor VIII concentrate, was demonstrated in patients with von Willebrand disease of all types in the WIL-31 study....
Lire la suite
von Willebrand disease (VWD) type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispecific nanobody, named KB-V13A12,...
Lire la suite
We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom.
Methods:...
Lire la suite
For the past decades, treatment for von Willebrand disease has essentially consisted of classic approaches, and only in the past few years has the need for more innovative strategies been recognized. To address the needs of groups of patients with similar phenotypes and bleeding, personalized therapeutic strategies are being developed, molecules designed for other bleeding disorders are being repositioned, and new hemostatic agents are being tested...
Lire la suite